ofatumumab (arzerra) Report issue

Biologics mAb Orphan Drug FDA Approved FDA Accelerated Approval FDA

Active Ingredient History

  • Now
Ofatumumab is a fully human monoclonal antibody to CD20, which appears to provide rapid B-cell depletion. Under the brand name Kesimpta, it is approved for the treatment of multiple sclerosis in the United States as well as in the European Union and other regions. Under the brand name Arzerra, it is approved for the treatment of certain types of chronic lymphocytic leukemia (CLL) in the United States. It is sold by Novartis under license from Genmab.   Wikipedia

More Chemistry
  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$86.6318 - $6812.4000
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

2f2 | arzerra | gsk1841157 | humax-cd20 | humax-cd20 2f2 | humax-cd20, 2f2 | immunoglobulin g1, anti-(human cd20 (antigen))(human monoclonal humax-cd20 heavy chain), disulfide with human monoclonal humax-cd20 kappa-chain, dimer | ofatumumab | ofatumumabum


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue